LGVN vs. GNPX, THAR, ENSC, DRUG, ARTL, GTBP, XCUR, PTPI, SNGX, and CPHI
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Genprex (GNPX), Tharimmune (THAR), Ensysce Biosciences (ENSC), Bright Minds Biosciences (DRUG), Artelo Biosciences (ARTL), GT Biopharma (GTBP), Exicure (XCUR), Petros Pharmaceuticals (PTPI), Soligenix (SNGX), and China Pharma (CPHI). These companies are all part of the "pharmaceutical preparations" industry.
Genprex (NASDAQ:GNPX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
Genprex presently has a consensus price target of $10.00, suggesting a potential upside of 308.16%. Longeveron has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Given Genprex's higher probable upside, analysts clearly believe Longeveron is more favorable than Genprex.
Longeveron has higher revenue and earnings than Genprex. Longeveron is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.
Genprex has a beta of -0.54, meaning that its stock price is 154% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.
Genprex has a net margin of 0.00% compared to Genprex's net margin of -3,020.17%. Genprex's return on equity of -209.14% beat Longeveron's return on equity.
Genprex received 191 more outperform votes than Longeveron when rated by MarketBeat users. However, 87.50% of users gave Longeveron an outperform vote while only 65.13% of users gave Genprex an outperform vote.
In the previous week, Genprex had 3 more articles in the media than Longeveron. MarketBeat recorded 4 mentions for Genprex and 1 mentions for Longeveron. Genprex's average media sentiment score of 0.70 beat Longeveron's score of 0.00 indicating that Longeveron is being referred to more favorably in the news media.
14.1% of Genprex shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 11.5% of Genprex shares are held by insiders. Comparatively, 24.3% of Longeveron shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Longeveron beats Genprex on 10 of the 15 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
